Scientists Block Alzheimer's Protein in Mice, See Brain Gains

After nearly 20 years of research, scientists at ETH Zurich discovered a new way to fight Alzheimer's disease by targeting a protein no one suspected was part of the problem.

Professor Ursula Quitterer and her team developed an experimental compound called "Compound 10" that prevented brain damage in mice with Alzheimer's. The treatment stopped harmful protein clumps from forming inside nerve cells, helping those cells survive longer and function better.

The breakthrough began with brain tissue samples from dementia patients in Cairo. Quitterer used those samples to investigate an enzyme called GRK2, which helps cells respond to stress and supports normal brain function.

Her team discovered that in people with dementia, unusually large amounts of inactive GRK2 clump together inside brain cells. These clumps collect on mitochondria, the energy factories of cells, blocking their pores and starving cells of the fuel they need to survive.

The inactive GRK2 also appeared to increase production of amyloid beta, the protein fragment considered a main cause of Alzheimer's. That creates a vicious cycle where amyloid beta stresses nerve cells, which produces more inactive GRK2, which makes more amyloid beta.

Compound 10 breaks that cycle. In mice, it prevented GRK2 from forming clumps, allowed mitochondria to work properly, and reduced amyloid buildup. Nerve cells maintained their function and avoided dying.

The effects reached beyond the brain. Treated mice showed improved heart function and fewer signs of aging. Older animals even developed less gray hair.

Why This Inspires

The research took two decades partly because Alzheimer's studies move slowly. Each experiment with older mice requires one and a half to two years before researchers can draw conclusions and design the next test.

But that patience paid off with something genuinely new. Most Alzheimer's medications can only delay progression by several months at best. Compound 10 works through a completely different biological pathway than existing drugs.

That difference matters. Because it operates through a separate mechanism, Compound 10 could potentially work alongside current treatments rather than replace them. Combining approaches may one day improve quality of life for people with Alzheimer's in ways a single medication cannot.

Quitterer and ETH Zurich are now searching for a company to help move Compound 10 toward human trials. The basic research phase is complete, and they've applied for a patent.

The road from mouse studies to human treatment remains long, but discovering an entirely new target protein opens doors that didn't exist before.